Latest News

A selection of recent news and views from Catapult Ventures follows...

Extra £6.5m secured by tech firm which uses AI to speed up scientific discovery as it eyes US expansion

A tech spin-out from the University of Manchester, which uses AI to curate masses of biomedical data to help scientists speed up research and development, has secured a £6.5m boost. Biorelate has completed a Series A investment round led by...

Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)

Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development. This nomination decision w...

Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in healthy volunteers evaluating the Company's lead drug candidate RESP-X, a new anti-virulence therapy to treat P...

Biorelate and Copyright Clearance Centre announce strategic integration

Manchester, UK.  Biorelate Limited (“Biorelate”) and CCC (Copyright Clearance Center), today announced a strategic integration. Biorelate’s customers will immediately have the option to access subscription-only scholarly art...

First Choice Neurology partners with Cytox

November 7, 2022 – First Choice Neurology (FCN), the largest neurology group in the U.S. with more than 41 facilities in six Florida counties and services at 35 major hospitals, has partnered with U.K-based Cytox to become the first pra...

From our portfolio

CanCertain

Diagnostics

CanCertain (formerly CLYZ Labs) is developing a testing service to select the best drug therapy f...

viewview our portfolio

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email